search
Back to results

DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 2
Locations
Taiwan
Study Type
Interventional
Intervention
AM 5 + DM 0
AM 5 + DM 2.5
AM 5 + DM 7.5
AM 5 + DM 30
Sponsored by
TSH Biopharm Corporation Limited
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring amlodipine, DMTA07, hypertension

Eligibility Criteria

50 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female patient aged between 50 to 75 years old (both included);
  2. Patient with mild to moderate essential hypertension at enrollment, which defined as the following:

    Patient must have mean sitting SBP ≥140 and <180 mmHg or mean sitting DBP ≥90 and <110 mmHg at enrollment;

  3. Patient with normal serum potassium;
  4. Patient or his/her legally acceptance representative has signed the written informed consent form.

Exclusion Criteria:

  1. Patient with severe hypertension (mean sitting DBP ≥ 110 mmHg or mean sitting SBP ≥ 180 mmHg);
  2. Patient with secondary hypertension, such as coarctation of aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc;
  3. Patient is under treatment with beta-blocker prior to enrollment;
  4. A definite diagnosis or unstable of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, arrhythmia and heart failure within 3 months before signing the written informed consent form;
  5. Patient with concomitant endocrine diseases or type 1 Diabetes Mellitus;
  6. Patient with type 2 Diabetes Mellitus with poor glucose control (glycosylated hemoglobin > 9% or fasting blood sugar > 250 mg/dL at enrollment) or under insulin treatment;
  7. Patient with clinically unstable disease such as known collagen or auto-immune disease or other malignant disease requiring current medication;
  8. Patient with bilateral renal artery stenosis, solitary kidney or post renal transplant;
  9. Patient with clinically relevant hematological disease;
  10. Hepatic or renal dysfunction as defined by the following parameters:

    • ALT or AST > 2 times upper limit of normal,
    • Total bilirubin > 2 times upper limit of normal,
    • Serum creatinine >2.0 mg/dl;
  11. Female patient who is pregnant or lactating;
  12. Patient with substance abuse (including alcohol) history for the past two years;
  13. Known or suspected contraindications, including allergy to DMTA07 or calcium channel blockers;
  14. Patient received other investigational drug or device within 30 days before signing the written informed consent form;
  15. Patient with any other serious disease considered by the investigator(s) not in the condition to enter the trial.

Sites / Locations

  • E-DA Hospital
  • Taichung Veterans General Hospital
  • National Taiwan University Hospital
  • Mackay Memorial Hospital
  • Cheng Hsin General Hospital
  • Taipei Veterans General Hospital
  • Tri-Service General Hospital
  • Chang Gung Memorial Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Experimental

Experimental

Experimental

Arm Label

AM 5 + DM 0

AM 5 + DM 2.5

AM 5 + DM 7.5

AM 5 + DM 30

Arm Description

Amlodipine 5 mg + DMTA07 0mg, once daily

Amlodipine 5 mg + DMTA07 2.5mg, once daily

Amlodipine 5 mg + DMTA07 7.5mg, once daily

Amlodipine 5 mg + DMTA07 30mg, once daily

Outcomes

Primary Outcome Measures

*SBP reduction=SBP each visit- SBPvisit2
The primary objective of this study is to compare the sitting systolic blood pressure (mmHg) reduction* between four dose regimens, the baseline is defined as the actual SBP value after 2 weeks of amlodipine run-in period

Secondary Outcome Measures

The secondary objectives of the study include: Efficacy/Safety
Efficacy: To compare the sitting diastolic blood pressure (mmHg) reduction* between four dose regimens, the baseline is defined as the actual DBP value after 2 weeks of amlodipine run-in period To evaluate the percentage of SBP reduction in four treatment regimens To evaluate the changes of blood pressure (mmHg) in different clusters; such as diabetes etc. Safety: To evaluate the pulse rate changes To evaluate incidences of adverse events To evaluate the change of laboratory test results from baseline

Full Information

First Posted
June 3, 2012
Last Updated
November 11, 2015
Sponsor
TSH Biopharm Corporation Limited
search

1. Study Identification

Unique Protocol Identification Number
NCT01614366
Brief Title
DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension
Official Title
A Phase II Study to Explore the Effect of Different Dose of DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
November 2015
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
May 2014 (Actual)
Study Completion Date
May 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
TSH Biopharm Corporation Limited

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to compare the different dose of DMTA07 (DM) combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy.
Detailed Description
To compare the different dose of DM combine with amlodipine in the treatment of mild to moderate essential hypertension, and to define the optimized dose of DM in the combination therapy. The purpose of this study is to compare the antihypertensive efficacy and tolerability of different dose of DM combines with amlodipine treatment, further to explore the optimized combination dose of DM.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
amlodipine, DMTA07, hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Factorial Assignment
Masking
Participant
Allocation
Non-Randomized
Enrollment
111 (Actual)

8. Arms, Groups, and Interventions

Arm Title
AM 5 + DM 0
Arm Type
Active Comparator
Arm Description
Amlodipine 5 mg + DMTA07 0mg, once daily
Arm Title
AM 5 + DM 2.5
Arm Type
Experimental
Arm Description
Amlodipine 5 mg + DMTA07 2.5mg, once daily
Arm Title
AM 5 + DM 7.5
Arm Type
Experimental
Arm Description
Amlodipine 5 mg + DMTA07 7.5mg, once daily
Arm Title
AM 5 + DM 30
Arm Type
Experimental
Arm Description
Amlodipine 5 mg + DMTA07 30mg, once daily
Intervention Type
Drug
Intervention Name(s)
AM 5 + DM 0
Other Intervention Name(s)
Amlodipine (AM), DMTA07 (DM)
Intervention Description
Amlodipine 5 mg + DMTA07 0mg, once daily
Intervention Type
Drug
Intervention Name(s)
AM 5 + DM 2.5
Other Intervention Name(s)
Amlodipine (AM), DMTA07 (DM)
Intervention Description
Amlodipine 5 mg + DMTA07 2.5mg, once daily
Intervention Type
Drug
Intervention Name(s)
AM 5 + DM 7.5
Other Intervention Name(s)
Amlodipine (AM), DMTA07 (DM)
Intervention Description
Amlodipine 5 mg + DMTA07 7.5mg, once daily
Intervention Type
Drug
Intervention Name(s)
AM 5 + DM 30
Other Intervention Name(s)
Amlodipine (AM), DMTA07 (DM)
Intervention Description
Amlodipine 5 mg + DMTA07 30mg, once daily
Primary Outcome Measure Information:
Title
*SBP reduction=SBP each visit- SBPvisit2
Description
The primary objective of this study is to compare the sitting systolic blood pressure (mmHg) reduction* between four dose regimens, the baseline is defined as the actual SBP value after 2 weeks of amlodipine run-in period
Time Frame
14 weeks
Secondary Outcome Measure Information:
Title
The secondary objectives of the study include: Efficacy/Safety
Description
Efficacy: To compare the sitting diastolic blood pressure (mmHg) reduction* between four dose regimens, the baseline is defined as the actual DBP value after 2 weeks of amlodipine run-in period To evaluate the percentage of SBP reduction in four treatment regimens To evaluate the changes of blood pressure (mmHg) in different clusters; such as diabetes etc. Safety: To evaluate the pulse rate changes To evaluate incidences of adverse events To evaluate the change of laboratory test results from baseline
Time Frame
14 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female patient aged between 50 to 75 years old (both included); Patient with mild to moderate essential hypertension at enrollment, which defined as the following: Patient must have mean sitting SBP ≥140 and <180 mmHg or mean sitting DBP ≥90 and <110 mmHg at enrollment; Patient with normal serum potassium; Patient or his/her legally acceptance representative has signed the written informed consent form. Exclusion Criteria: Patient with severe hypertension (mean sitting DBP ≥ 110 mmHg or mean sitting SBP ≥ 180 mmHg); Patient with secondary hypertension, such as coarctation of aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc; Patient is under treatment with beta-blocker prior to enrollment; A definite diagnosis or unstable of cardiovascular disease, including angina pectoris, myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, transient ischemic attack, stroke, arrhythmia and heart failure within 3 months before signing the written informed consent form; Patient with concomitant endocrine diseases or type 1 Diabetes Mellitus; Patient with type 2 Diabetes Mellitus with poor glucose control (glycosylated hemoglobin > 9% or fasting blood sugar > 250 mg/dL at enrollment) or under insulin treatment; Patient with clinically unstable disease such as known collagen or auto-immune disease or other malignant disease requiring current medication; Patient with bilateral renal artery stenosis, solitary kidney or post renal transplant; Patient with clinically relevant hematological disease; Hepatic or renal dysfunction as defined by the following parameters: ALT or AST > 2 times upper limit of normal, Total bilirubin > 2 times upper limit of normal, Serum creatinine >2.0 mg/dl; Female patient who is pregnant or lactating; Patient with substance abuse (including alcohol) history for the past two years; Known or suspected contraindications, including allergy to DMTA07 or calcium channel blockers; Patient received other investigational drug or device within 30 days before signing the written informed consent form; Patient with any other serious disease considered by the investigator(s) not in the condition to enter the trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jaw-Wen Chen, Doctor
Organizational Affiliation
VGHTP
Official's Role
Principal Investigator
Facility Information:
Facility Name
E-DA Hospital
City
Kaohsiung
ZIP/Postal Code
824
Country
Taiwan
Facility Name
Taichung Veterans General Hospital
City
Taichung
ZIP/Postal Code
40705
Country
Taiwan
Facility Name
National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
100
Country
Taiwan
Facility Name
Mackay Memorial Hospital
City
Taipei
ZIP/Postal Code
104
Country
Taiwan
Facility Name
Cheng Hsin General Hospital
City
Taipei
ZIP/Postal Code
112
Country
Taiwan
Facility Name
Taipei Veterans General Hospital
City
Taipei
ZIP/Postal Code
112
Country
Taiwan
Facility Name
Tri-Service General Hospital
City
Taipei
ZIP/Postal Code
114
Country
Taiwan
Facility Name
Chang Gung Memorial Hospital
City
Taoyuan County
ZIP/Postal Code
333
Country
Taiwan

12. IPD Sharing Statement

Learn more about this trial

DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension

We'll reach out to this number within 24 hrs